Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

Applying Pharmacogenomics in the Therapeutics of Pulmonary Diseases
237
45. Cigarette smoking and health. American Thoracic Society. American Journal of
Respiratory and Critical Care Medicine 1996;153:861–5.
46. Wood AM, Stockley RA. The genetics of chronic obstructive pulmonary disease.
Respiratory Research 2006;7:130.
47. Provinciali M, Cardelli M, Marchegiani F. Inflammation, chronic obstructive pulmonary
disease and aging. Current Opinion in Pulmonary Medicine 2011;17(Suppl 1):S3–10.
48. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD:
A summary of the ATS/ERS position paper. The European Respiratory Journal 2004;​
23:932–46.
49. Wouters EF. Local and systemic inflammation in chronic obstructive pulmonary
disease. Proceedings of the American Thoracic Society 2005;2:26–33.
50. Churg A, Wang RD, Tai H, Wang X, Xie C, Wright JL. Tumor necrosis factor-alpha
drives 70% of cigarette smoke-induced emphysema in the mouse. American Journal of
Respiratory and Critical Care Medicine 2004;170:492–8.
51. Sevenoaks MJ, Stockley RA. Chronic obstructive pulmonary disease, inflammation
and co-morbidity—A common inflammatory phenotype? Respiratory Research
2006;7:70.
52. Huang SL, Su CH, Chang SC. Tumor necrosis factor-alpha gene polymorphism in
chronic bronchitis. American Journal of Respiratory and Critical Care Medicine
1997;156:1436–9.
53. Sakao S, Tatsumi K, Igari H, Shino Y, Shirasawa H, Kuriyama T. Association of
tumor necrosis factor alpha gene promoter polymorphism with the presence of chronic
obstructive pulmonary disease. American Journal of Respiratory and Critical Care
Medicine 2001;163:420–2.
54. Sakao S, Tatsumi K, Igari H, et al. Association of tumor necrosis factor-alpha gene
promoter polymorphism with low attenuation areas on high-resolution CT in patients
with COPD. Chest 2002;122:416–20.
55. Hersh CP, Demeo DL, Lange C, et al. Attempted replication of reported chronic
obstructive pulmonary disease candidate gene associations. American Journal of
Respiratory Cell and Molecular Biology 2005;33:71–8.
56. Sandford AJ, Chagani T, Weir TD, Connett JE, Anthonisen NR, Pare PD. Susceptibility
genes for rapid decline of lung function in the lung health study. American Journal of
Respiratory and Critical Care Medicine 2001;163:469–73.
57. Keppel KG, Pearcy JN, Heron MP. Is there progress toward eliminating
racial/ethnic disparities in the leading causes of death? Public Health Reports 2010;​
125:689–97.
58. Cho MH, Castaldi PJ, Wan ES, et al. A genome-wide association study of COPD identifies
a susceptibility locus on chromosome 19q13. Human Molecular Genetics 2012;​
21:947–57.
59. Pillai SG, Ge D, Zhu G, et al. A genome-wide association study in chronic obstructive
pulmonary disease (COPD): Identification of two major susceptibility loci. PLoS
Genetics 2009;5:e1000421.
60. Cho MH, McDonald ML, Zhou X, et al. Risk loci for chronic obstructive pulmonary
disease: A genome-wide association study and meta-analysis. The Lancet 2014;​
2:214–25.
61. Palmer LJ, Celedon JC, Chapman HA, Speizer FE, Weiss ST, Silverman EK. Genomewide
linkage analysis of bronchodilator responsiveness and post-bronchodilator
spirometric phenotypes in chronic obstructive pulmonary disease. Human Molecular
Genetics 2003;12:1199–210.
62. Albert P, Agusti A, Edwards L, et al. Bronchodilator responsiveness as a phenotypic
characteristic of established chronic obstructive pulmonary disease. Thorax 2012;​
67:701–8.